Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Damon Bass's publication output changed over time?
ScholarIQpublication output · 2011–2021
Output grew100% over the shown period — from 1 works in 2011 to 2 in 2021.
1
1
2
2
2
2
201120132017201820202021
What are the most-cited papers on Damon Bass?
ScholarIQmost cited works
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
William Stohl, Andreas Schwarting, Masato Okada, Morton Scheinberg, Andrea Doria, Anne E. Hammer, C. Kleoudis, James Groark, Damon Bass, Norma Lynn Fox, David A. Roth, David Gordon
Arthritis & Rheumatology. 2017422 CitationsOPEN ACCESS
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Fengchun Zhang, Sang‐Cheol Bae, Damon Bass, Myron Chu, Sally Egginton, David Gordon, David A. Roth, Jie Zheng, Yoshiya Tanaka
Annals of the Rheumatic Diseases. 2018297 CitationsOPEN ACCESS
Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review
Evelyn Sarnes, Leslie J. Crofford, Maria Watson, Greg Dennis, Hong Kan, Damon Bass
Clinical Therapeutics. 2011261 CitationsOPEN ACCESS
Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
Anadi Mahajan, Justyna Amelio, Kerry Gairy, Gavneet Kaur, Roger A. Levy, David A. Roth, Damon Bass
Lupus. 2020208 CitationsOPEN ACCESS
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
Brad H. Rovin, Richard Furie, Y K Onno Teng, Gabriel Contreras, Ana Malvar, Xueqing Yu, Beulah Ji, Yulia Green, Tania Gonzalez‐Rivera, Damon Bass, Jennifer Gilbride, Chun-Hang Tang, David A. Roth
Kidney International. 2021207 CitationsOPEN ACCESS
Related on ScholarIQ
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
Paper
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Paper
Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review
Paper
Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
Paper
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
Paper
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
Paper